Form HealthvsSequence by WeightWatchers

Form Health is a telehealth obesity clinic, not a drug itself. After an online intake, you are matched with a care team led by an ABOM-certified obesity-medicine physician (or advanced practice provider) plus a registered dietitian. They review your history and, when medically appropriate, prescribe FDA-approved anti-obesity medications such as Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), or Contrave. Most of these are GLP-1-based drugs that mimic gut hormones to slow stomach emptying, reduce appetite, and curb cravings (tirzepatide also acts on the GIP receptor). Care is delivered through video visits, unlimited messaging, and an app for weight and food tracking, combining medication with nutrition and behavior change.

Sequence is a telehealth platform, not a drug. You complete an online health-history questionnaire, then have a video visit with a board-certified clinician who decides whether a prescription weight-loss medication is safe and appropriate for you. The medications prescribed are mostly GLP-1 (and dual GLP-1/GIP) receptor agonists such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda); non-GLP-1 options like metformin or naltrexone/bupropion may also be used when appropriate. These drugs mimic gut hormones that slow stomach emptying, blunt appetite, and increase fullness, so many people eat less without constant hunger. Layered on top is WeightWatchers' behavioral program: the Points food system, dietitian access, fitness guidance, and a GLP-1 Success Program focused on protein intake and muscle preservation during weight loss.

Form Health reports an average of 16% body-weight loss at 18 months across its patients (with and without medication), but this is the company's own internal program data, not an independently published, peer-reviewed clinical trial, so treat it as a marketing claim rather than proof. The medications Form prescribes do have strong trial evidence. In the STEP-1 trial (NEJM, 2021), adults on weekly semaglutide 2.4 mg (Wegovy) lost an average of about 14.9% of body weight at 68 weeks versus 2.4% on placebo. In SURMOUNT-1 (NEJM, 2022), tirzepatide (Zepbound) produced average losses of roughly 15% to 21% over 72 weeks depending on dose (about 15.0% at 5 mg up to 20.9% at 15 mg in the primary analysis, and higher, up to about 22.5%, among adherent participants). Real-world telehealth outcomes are often somewhat lower than trial figures because of drug discontinuation and adherence.

Real-world and trial evidence for these medications is genuinely strong, though the platform-specific figures should be read with caution. A 2024 retrospective analysis in the journal Obesity (Ard et al.) of the WeightWatchers/Sequence telehealth program reported that, among patients with complete data at 12 months, average weight loss was about 19.4% of initial body weight, with roughly 21.2% on tirzepatide and the semaglutide formulations (Wegovy and Ozempic) in the mid-teens, broadly 13 to 15 percent. A key caveat: of the 53,590 patients who started treatment, only about 6,089 had complete 12-month data, so these completer averages likely overstate typical results because people who stopped early or regained are underrepresented. These outcomes are broadly in line with the pivotal drug trials: semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks in STEP 1 (NEJM 2021); tirzepatide produced roughly 20.9% (15 mg, treatment-regimen estimand) and up to about 22.5% over 72 weeks in SURMOUNT-1 (NEJM 2022); and in the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide outperformed semaglutide, about 20.2% versus 13.7% at 72 weeks. Individual results vary widely and depend heavily on staying on the medication and engaging with the program.

Side effects come from the prescribed medication, not the service itself. The most common with GLP-1 drugs (Wegovy, Zepbound, Saxenda) are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, usually mild-to-moderate and worst during dose escalation. Contrave can cause nausea, headache, constipation, insomnia, and raised blood pressure. Serious but uncommon risks include acute pancreatitis, gallbladder disease, and kidney injury from dehydration. GLP-1 drugs carry an FDA boxed warning for thyroid C-cell tumors seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Seek prompt medical care for severe, persistent abdominal pain.

The most common side effects come from the medications, not the platform, and are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst when starting or increasing the dose and often easing over time. Slow dose titration and dietary adjustments can help. Less common but serious risks include an FDA boxed warning for thyroid C-cell tumors (based on rodent studies; human risk is not established), along with reported cases of pancreatitis, gallbladder disease and gallstones, kidney injury from dehydration, and, with tirzepatide, possible reduced absorption of oral contraceptives. Rapid weight loss can also cause loss of muscle mass, which the WW GLP-1 Success Program tries to counter with high-protein and strength guidance. Seek prompt medical attention for severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction, and report concerning symptoms to your care team. This is not a complete list of side effects.

As of 2026, Form Health's self-pay membership is about $299/month, which is HSA/FSA-eligible and covers physician and dietitian visits, messaging, and the app, but not medications or lab work. GLP-1 drugs can cost roughly $500 to $1,300 or more per month at cash price (manufacturer savings programs and lower-cost direct-pay vials for Wegovy and Zepbound can reduce this). Alternatively, Form can bill visits, labs, and medications through most major private insurance plans, in which case you pay only copays and deductibles, which can dramatically lower total cost. Medicare is more limited: by federal law it does not cover a drug prescribed solely for weight loss, so a GLP-1 is generally covered only when prescribed for a separate approved indication such as type 2 diabetes or cardiovascular risk reduction. Coverage varies widely by plan, so verify your specific benefits in writing before starting.

As of 2026, WW Clinic / Med+ membership is commonly advertised at about $25/month for the first two to three months, then roughly $74/month for the remainder of a 12-month plan, with month-to-month options reported around $149/month. Membership covers clinician visits, insurance coordination, labs, coaching, and the WW app, but the medication is billed separately. List prices for brand-name GLP-1s can run roughly $1,000 to $1,350 per month, but few people pay that: WeightWatchers and the manufacturers offer cash-pay programs that are far lower (for example, Novo Nordisk's self-pay Wegovy oral tablet has been offered near $149/month and WW has advertised cash-pay injectable starter pricing well under list), and commercial insurance, where it covers weight-loss GLP-1s, can drop out-of-pocket costs to roughly $25 to $150/month. Coverage and savings eligibility vary widely, so verify your specific plan and compare WW's drug pricing against pharmacy and manufacturer options before committing.

Form Health is for US adults 18 and older with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. You must have a primary care provider and have seen them within the past 12 months, since Form coordinates with (rather than replaces) your PCP. It is not appropriate for people seeking treatment for an eating disorder, those who are pregnant or breastfeeding, or anyone with contraindications to the prescribed medication. GLP-1 drugs like Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Always disclose your full medical history; the prescribing physician makes the final call.

The program is designed for US adults who meet clinical criteria for anti-obesity medication, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. The clinician makes the final call after reviewing your history and, in many cases, lab work. GLP-1 medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and they should not be used in pregnancy or by people with a prior serious hypersensitivity reaction to the drug. People with a history of pancreatitis, gallbladder disease, gastroparesis, kidney problems, or diabetic retinopathy need careful evaluation. The program is not a substitute for in-person care and is not appropriate for those seeking medication without medical oversight.